Five Star Equities releases regular market updates so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.FiveStarEquities.com and get exclusive access to our numerous stock reports.
Harvard Apparatus Regenerative Tech Inc. (NASDAQ: HART) shares increased 16.75 percent to close at $9.90 a share Monday. The stock traded between $8.34 and $10.30 on volume 651,098 shares traded. The company reported a net loss of $2.6 million, or $0.34 per diluted share, for the fourth quarter of 2013, compared to a $2.0 million net loss, or $0.25 per diluted share, a year ago. Shares of Harvard Apparatus are up over 100.0 percent year-to-date.
Get more information on Harvard Apparatus free access to the in-depth equity report at:
Hydrogenics Corp. (NASDAQ: HYGS)(TSX: HYG) shares surged 15.46 percent to close at $33.76 a share Monday. The stock traded between $31.05 and $35.45 on volume 960,315 shares traded. The company reported revenues were $11.0 million for the fourth quarter of 2013, an increase of 12.0 percent when compared to a year ago. Shares of Hydrogenics are up approximately 75.0 percent year-to-date.
Get more information on Hydrogenics and free access to the in-depth equity report at:
Montage Technology Group Ltd. (NASDAQ: MONT) shares spiked 20.40 percent to close at $20.66 a share Monday. The stock traded between $20.07 and $21.19 on volume of 2.49 million shares traded. The company announced that it has received a non-binding acquisition proposal from Shanghai Pudong Science and Technology Investment Co., Ltd. of $21.50 in cash per ordinary share. Shares of Montage are up approximately 26.0 percent year-to-date.
Get more information on Montage and free access to the in-depth equity report at:
Northwest Biotherapeutics, Inc. (NASDAQ: NWBO) shares soared 29.55 percent to close at $7.85 a share Monday. The stock traded between $6.36 and $8.25 on volume of 6.16 million shares traded. The company announced that it received two German approvals for DCVax, its lead immunotherapy product. Shares of Northwest Biotherapeutics are up approximately 110.0 percent year-to-date.
Get more information on Northwest Biotherapeutics and free access to the in-depth equity report at:
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Five Star Equities has no financial relationship with any company whose stock is mentioned in this release.
Five Star Equities